Heart Care Company HeartFlow Agrees to $2.4 Billion SPAC Merger to Go Public

HeartFlow, a precision heart care company, announced today a deal to combine with the special purpose acquisition company (SPAC) Longview Acquisition Corp. II (NYSE: LGV).

The SPAC merger will bring $400 million in cash for growth capital and product development. The deal values the healthcare company at $2.4 billion.

“We believe that our non-invasive, artificial intelligence-enabled, cloud-based enterprise software solution can transform cardiovascular care with risk assessment, diagnosis planning and treatment management,” said John H. Stevens, MD, President, CEO and Co-Founder of HeartFlow.

“Importantly, we have brought together a talented group of individuals with deep expertise in technology, cardiovascular medicine, and the business of healthcare and a deep commitment to patients to deliver on this vision. I’m incredibly proud of the HeartFlow team in reaching this important milestone.”

The company is looking to tap into the $10 billion total addressable market opportunity that is likely to expand to more than $50 billion over the coming years. HearthFlow’s products are cleared and available in the U.S., the EU, the U.K., and Japan.

“For us, HeartFlow’s compelling investment attributes leapt off the page: addressing a massive unmet medical need with proprietary, innovative technology through a highly attractive business model that experts widely cite as delivering superior patient outcomes at lower systemic costs,” commented Larry Robbins, Chairman of Longview and CEO of Glenview.

Once the transaction is closed, the company will be listed on the New York Stock Exchange (“NYSE”) under the symbol “HFLO.”

You May Also Be Interested In

• Paramount Global (PARA) and Skydance are closer to a merger - CNBC
• Perrigo (PRGO) Receives Binding Offer to Divest its HRA Pharma Rare Diseases Business for up to EUR 275M
• GXO Logistics, Inc. (GXO) Launches Notes Offering